

POSTER PRESENTATIONS

The following are abstract holders that confirmed their live participation at the time of printing.

#	Title of Abstract	Author(s)
0005	Role of Growth Differentiation Factor -15 and Neuregulin -1 in Patients with Coronary Artery Disease	1,2Monika Samra, 2Indu Arora, 3Rajiv Narang, 1*Kamna Srivastava
0012	Correlation of Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, and Colorectal Cancer Occurrence	Chong-Chi Chiu, MDa,b,c,*; Chao-Ming Hung, MD, PhDa,c
0013	Association Between Insulin Resistance and Body Composition in Elderly Individuals with Type 2 Diabetes Mellitus: A cross-sectional Study	Amulya varshini Banka1; Shravani Divity2; Arpan Turimula3; Yethindra Vityala4; Krishna Chaitanya Meduri5; Sai Praneeth Duvvuri5; Tugolbai Tagaev6
0014	Survodutide, a Glucagon Receptor/glucagon-like peptide-1 Receptor (GCGR/GLP-1R) Dual Agonist, Improves Cardiometabolic Parameters in Adults with Obesity: Analysis of a Placebo-controlled, Randomized Phase 2 Trial	Carel W. Le Roux1, Oren Steen2, Kathryn J. Lucas3, Elif I. Ekinci4, Elena Startseva5, Anna Unseld6, Anita M. Hennige7
0015	Survodutide, a Glucagon Receptor/glucagon-like Peptide-1 Receptor (GCGR/GLP-1R) Dual Agonist, Improves Metabolic Risk Factors in Adults Living with Obesity: Analysis of a Placebo-controlled, Randomized Phase 2 Trial	Carel W. Le Roux1, Oren Steen2, Kathryn J. Lucas3, Elif I. Ekinci4, Elena Startseva5, Anna Unseld6, Anita M. Hennige7
0016	Analysis of Glucose Biomarkers in Phase I and Phase II Studies of Survodutide in People with Type 2 Diabetes or Living with Overweight/Obesity	Elif I. Ekinci1, Jorge Arrubla2, Anita M. Hennige3, Corinna Schoelch4
0017	Impact of Insulin Resistance and Chronic Low-Grade Systemic Inflammation on Vascular Rigidity in Patients with Arterial Hypertension and Non-Alcoholic Fatty Liver Disease	Poshitha Kondadasula1; Sri Ram Charan Gundapaneni2; Rohini Kaku3; Yethindra Vityala4
0018	Influence of Nutrient Composition on Postprandial Glycemic Response in Individuals with Cardiometabolic Risk Monitored Using Continuous Glucose Monitoring	Alannis Daniela Zapatero Jimenez1, RD; Jocelyn Madrigal Acevedo1, RD, PhD; Eliud Salvador Aguilar Barrera1, RD, MSc.
0019	The pan-PPAR Agonist Lanifibranol Improves Liver Inflammation, Ballooning, and Fibrosis in a Diet-induced Obese MASH Hamster Model of Binge Drinking.	François Briand1, Estelle Grasset1, Claire Bigot1, Natalia Breyner1, Thierry Sulpice1
0020	Aldosterone Dysregulation and Type 2 Diabetes Mellitus Are Associated With Prevalent Risk of Hypertension: BREAKTHROUGH Risk Study	Raymond Townsend1, Abiy Agiro2, Shan Luan2, Kaylen Brzozowski3, Erick Moyneur4, Paule Tetreault-Langlois4, Joanna Huang2, Karthik Linganathan2
0023	PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)	Gerald F. Watts, D.Sc., M.D., Ph.D., Robert A. Hegele, M.D., Robert S. Rosenson, M.D., Ira J. Goldberg, M.D., Antonio Gallo, M.D., Ph. D., Ann Mertens, M.D., Ph.D., Alexis Baass, M.D., M.Sc., Ran Fu, Ph.D., Ma'an Muhsin, M.D., Jennifer Hellawell, M.D., Nicholas J. Leeper, M.D., Daniel Gaudet, M.D., Ph.D., on behalf of the PALISADE Study Group*
0024	Translational Rodent Models to Feature the Different Phenogroups of Patients Suffering from Heart Failure with Preserved Ejection Fraction and Associated Metabolic Comorbidities	Assaly R1, Dubroca C1, Waget A1, Shinohara M2, Kageyama Y2, Briand F3, Sulpice T1,3
0026	Effects Of Late Onset Estradiol Treatment On Insulin Resistance And Lipid Metabolism In High-Fat-Fed Ovariectomized Female Mice	CRUZ, A.G.1; SANTOS, J.D.M.1; TRINCA, B.M.F.; SANTOS, A.R.M.; CAMPOREZ, J.P.1
0027	Effectiveness of empagliflozin in patients with heart failure and COPD: Results from EMPEROR-Preserved and EMPEROR-Reduced	Stephan von Haehling1, Javed Butler2, and Stefan D. Anker3 on behalf of the EMPEROR Executive Committee
0029	Performance of Established and Novel Non-invasive Tests, Including New Clinical and Metabolomics-Based Machine Learning Models, for Detecting MASH with Fibrosis Stages F2-F3: A First-in-Class Approach in the post-Resmetirom approval era	"Konstantinos Stefanakis MD,1* Geltrude Mingrone MD,2 Jacob George MD,3 Christos S. Mantzoros MD DSc1,4"
0033	Role of Single Nucleotide Variants of the POC5 Gene in the Development of Obstructive Sleep Apnea Syndrome in Children with Metabolically Unhealthy Obesity	Aleksandr Abaturvov, Anna Nikulina, Dmytro Nikulin, Daryna Dikhtyarenko
0034	Inherited Stress Vulnerability Exacerbates Obesity-induced Metabolic Alterations Through Dysfunctional Adipose Tissue	Saumya Kishor Mehta, Michaela Ben-Shachar, Albert Pinhasov and Tovit Rosenzweig
0036	Causes of Death, Mortality Rates, and the Role of Socio-demographic Risk Factors and Biomarkers in Metabolic Dysfunction-associated Steatohepatitis Mortality in More than 18,000 Real World Patients from the United States	Jörn M. Schattenberg1, Claudio Sartini2, Ronald Herrera2, Mireia Raluy3, Mark Yates4, Ramy Younes5
0037	Glucagon and GLP-1 Receptor Dual Agonist Survodutide Improved Liver Histology in People with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis: Results from a Randomized, Double-blind, Placebo-controlled Phase 2 Trial	Arun J. Sanyal1, Pierre Bedossa2, Mandy Fraessdorf3, Guy W. Neff4, Eric Lawitz5, Elisabetta Bugianesi6, Quentin M. Anstee7, Samina Ajaz Hussain8, Philip N. Newsome9, Vlad Ratziu10, Azadeh Hosseini-Tabatabaei11, Jörn M. Schattenberg12, Mazen Nouredin13, Naim Alkhouri14,15, Ramy Younes8
0038	Finerenone in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) by Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Use: A FIDELITY Analysis	Ajay K. Singh,1,† Stefan D. Anker,2 Bertram Pitt,3 Peter Rossing,4,5 Luis M. Ruilope,6–8 Christiane Ahlers,9 Youssef M.K. Farag,10,11,† Marc Lambelet,12 Meike D. Brinker,13 Katja Rohwedder,14 Ted Chen,15 Gerasimos Filippatos,16 George L. Bakris,17 on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators
0039	Finerenone in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: Baseline and New-Onset Diabetes	John W. Ostrominski,1 Pardeep S. Jhund,2 Scott D. Solomon,1 John J.V. McMurray,3 on behalf of the FINEARTS-HF Investigators
0040	Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease	John W. Ostrominski,1 Brian L. Claggett,1 Zi Michael Miao,1 Gerasimos Filippatos,2 Akshay S. Desai,1 Pardeep S. Jhund,3 Alasdair Henderson,3 Meike Brinker,4 Patrick Schloemer,4 Prabhakar Viswanathan,4 Andrea Lage,4 Katja Rohwedder,4 Carolyn S.P Lam,5 Michele Senni,6 Sanjiv J. Shah,7 Adriaan A. Voors,8 Faiez Zannad,9 Peter Rossing,10; Luis M. Ruilope,11 Stefan D. Anker,12 Bertram Pitt,13 Rajiv Agarwal,14 John J.V. McMurray,3 Scott D. Solomon,1 Muthiah Vaduganathan1
0042	How Important is to Measure Insulin Secretion during Oral Glucose Tolerance Test?	T. Totomirova1, M. Arnaudova2, N. Kostadinov3
0043	Role of Coronary Artery Calcium in the Association Between Hormone Replacement Therapy Status and Incident Death and Cardiovascular Disease: the Multi-Ethnic Study of Atherosclerosis	Rachelle Bishay1, BS, Sina Kianoush1, MD MPH, April Kinninger1, MPH, Keishi Ichikawa1, MD PhD, Srikanth Krishnan1, MD MSc, Jairo Aldana-Bitar1, MD, Travis Benzinger1, MD, Nathan D. Wong2, PhD, Erin D. Michos3, MD MHS, Ahmed Ghanem1, MD, Marziyeh Bagheri1, MD, Hossein Hamidi1, MD, Matthew J. Budoff1, MD
0044	Comparing Biomarkers of Metabolic Inflammation: The Predictive Accuracy of Plasma Water T2 Exceeds That of High-Sensitivity C-Reactive Protein and Erythrocyte Sedimentation Rate	David P. Cistola M.D., Ph.D.a*, Alok K. Dwivedi Ph.D.b
0045	Prevalence of Hypercortisolism in Patients with Difficult-to-control Type 2 Diabetes: Final Results from CATALYST Part 1	John B. Buse, MD, PhD1, Steven E. Kahn, MB, ChB2, Vanita R. Aroda, MD3, Richard J. Auchus, MD, PhD4, Timothy Bailey, MD5, Irina Bancos, MD, MS6, Robert S. Busch, MD7, Elena Christofides, MD8, Ralph A. DeFronzo, MD9, Bradley Eilerman, MD, MHI10, James Findling, MD11, Vivian Fonseca, MD12, Oksana Hamidi, DO, MSCS13, Yehuda Handelsman, MD14, Harold J. Miller, MD15, Jonathan G. Ownby, MD16, John Parker, MD, ECNU17, Athena Philis-Tsimikas, MD18, Richard Pratley, MD19, Julio Rosenstock, MD20, Michael H. Shanik, MD21, Lance Sloan, MD, MSE22, Guillermo Umperierrez, MD23, Iulia Cristina Tudor, PhD24, Tina K. Schläpfl, PhD24, Daniel Einhorn, MD24 - on behalf of the CATALYST Investigators
0046	Prevalence of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes and Cardiovascular Disease: Results from CATALYST	Vivian Fonseca, MD1, Vanita R. Aroda, MD2, Matthew Budoff, MD3, Robert S. Busch, MD4, John B. Buse, MD, PhD5, Ralph A. DeFronzo, MD6, Bradley Eilerman, MD, MHI7, Yehuda Handelsman, MD8, Steven E. Kahn, MB, ChB9, Dan Lender, MD10, Jonathan G. Ownby, MD11, Jorge Plutzky, MD12, Julio Rosenstock, MD10, Michael H. Shanik, MD13, Lance Sloan, MD, MSE14, Guillermo Umperierrez, MD15, Iulia Cristina Tudor, PhD16, Daniel Einhorn, MD16 (on behalf of the CATALYST Investigators)

POSTER PRESENTATIONS

The following are abstract holders that confirmed their live participation at the time of printing.

#	Title of Abstract	Author(s)
0047	Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study	Rosario Pivonello ¹ , Giorgio Arnaldi ² , Richard J. Auchus ³ , Corin Badiu ⁴ , Robert S. Busch ⁵ , Salvatore Cannavo ⁶ , Ulrich Dischinger ⁷ , Georgiana A. Dobri ⁸ , Diane Donegan ⁹ , Atanaska Elenkova ¹⁰ , Pouneh K. Fazeli ¹¹ , Richard A. Feelders ¹² , Rogelio Garcia-Centeno ¹³ , Aleksandra Gilis-Januszewska ¹⁴ , Oksana Hamidi ¹⁵ , Zeina C. Hannoush ¹⁶ , Harold J. Miller ¹⁷ , Aurelian Emil Ranetti ¹⁸ , Monica Recasens ¹⁹ , Martin Reincke ²⁰ , Sergio Rovner ²¹ , Roberto Salvatori ²² , Julie Silverstein ²³ , Antonio Stigliano ²⁴ , Terzolo Massimo ²⁵ , Christina Wang ²⁶ , Kevin C.J. Yuen ²⁷ , Austin L. Hand ²⁸ , Iulia Cristina Tudor ²⁸ , Katherine A. Araque ²⁸ , Andreas G. Moraitis ²⁸
0048	Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)	Richard J. Auchus ¹ , Aleksandra Gilis-Januszewska ² , Corin Badiu ³ , Aurelian-Emil Ranetti ⁴ , Alexandra Kautzky-Willer ⁵ , Rosario Pivonello ⁶ , Georgiana Dobri ⁷ , Harold J. Miller ⁸ , Dan Niculescu ³ , Amer Al-Karadsheh ⁹ , Carmen Aresta ¹⁰ , Iulia Cristina Tudor ¹¹ , Hristina Pashova ¹¹ , Katherine Araque ¹¹ , Andreas Moraitis ¹¹
0049	Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results	Corin Badiu ¹ , Richard Auchus ² , Irina Bancos ³ , Ulrich Dischinger ⁴ , Amir H. Hamrahian ⁵ , Alexandra Kautzky-Willer ⁸ , Miguel Angel Mangas-Cruz ⁶ , Cary Mariash ⁷ , John Parker ¹⁰ , Rosario Pivonello ¹¹ , Aurelian Emil Ranetti ⁹ , Gadi Shlomai ¹² , Jeffrey Botbyl ¹³ , Andreas G. Moraitis ¹³ , Katherine A. Araque ¹³
0050	Prevalence of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes and High Blood Pressure: Results from CATALYST	Yehuda Handelsman MD ¹ , Vanita R. Aroda MD ² , Timothy Bailey MD ³ , Robert S. Busch MD ⁴ , John B. Buse MD, PhD ⁵ , Elena Christofides MD ⁶ , Ralph A. DeFronzo MD ⁷ , Bradley Eilerman MD, MH18, Vivian Fonseca MD ⁹ , Adline Ghazi MD ¹⁰ , Steven E. Kahn MB, ChB ¹¹ , Mark Kipnes MD ¹² , Dan Lender MD ¹³ , Jonathan G. Ownby MD ¹⁴ , Jean Park MD ¹⁰ , Julio Rosenstock MD ¹³ , Michael Shanik MD ¹⁵ , Lance Sloan MD, MSE ¹⁶ , Ron Swerdlow, MD ¹⁷ , Guillermo Umpierrez MD ¹⁸ , Iulia Cristina Tudor PhD ¹⁹ , Daniel Einhorn MD ¹⁹
0051	Genetic Predictors Associated with the Effectiveness of Non-pharmacological Methods of Treating Obesity in Children	Aleksandr Abatur, Anna Nikulina, Dmytro Nikulin, Daryna Dikhtyarenko
0052	Measures of Insulin Resistance (IR) Increase with Increasing BMI in a Population of Normoglycemic Working Adults	Judy Louie, MS, Dov Shiffman, PhD, James B. Meigs, MD, Lance Bare, PhD, Michael J. McPhaul, MD
0053	Sequential Measurements of Insulin Resistance (IR) in the Assessment of Individuals Participating In Diabetes Prevention Programs	Martha Brandon, Julia A. Larsen, RN, Michael J. McPhaul, MD
0054	Exploring Targeting Inflammasome Signaling: Ginsana-115 as Prime Driver in Insulin Resistance/ cardiovascular Risk (CVD) in Prototypal Brain Disorder: Schizophrenia	Autumn Carriere B.Sc.(Honors, Nursing); B.Sc.(Honors,Kinesology)-Research Associate, WKY Foundation Integrative Medicine, London, ON,Canada; Simon S Chiu MD PhD DABPN University of Western Ontario Prof Emeritus, London ON: Research Divison, WKY Viking Foundation Integrative Medicine London ON, Canada; Michel Woodbury MD Prof Univ. PR, PR (USA)< Mariwan Husni MD FRCP DPM, Chair Prof Psychiatry Gulf Medical Univeristy, Brahan Kingdom : John Copen MD FRCP< Univ. BC, Victoria Medical Campus Victoria BC; Canada; Allison Foskett, PhD clinical Psychologist, Univ Alberta, Edmonton Alberta, Ed Lui PHD Prof Pharmacology Univ Weteren Ontario London ON: President WKY Viking Foundation London ON Canada, Robbie Campbell MD FRCP, PProf Emeritus Univ Western Ontario London ON Canada
0055	Genetic Predictors Associated with the Effectiveness of Non-pharmacological Methods of Treating Obesity in Children	Aleksandr Abatur, Anna Nikulina, Dmytro Nikulin
0056	Effects on Muscle Mass, Fat, Waist Circumference, and Glycosylated Hemoglobin with the Use of Phentermine Combined with a Flexible Weight Loss Strategy	Cesar Ochoa, MD, PhD ¹ , Georgina Roano Iglesias, MD ² , and María Magdalena Valencia Gutiérrez, MD ³
0058	"Phase II Dose-selection, Randomized, Controlled Trial of Aldosterone Synthase Inhibitor Vicastrostat (BI 690517) With and Without Empagliflozin in Chronic Kidney Disease: Subgroup Analysis by Type 2 Diabetes Status"	Peter Rossing ^{1,2} , Sibylle J. Hauske ^{3,4} , Lisa Cronin ⁵ , Hiddo J. L. Heerspink ^{6,7} , Juliane Meyerhoff ³ , Shimoli V. Shah ⁵ , Zhichao Sun ⁵ , Dick de Zeeuw ⁶ , Katherine R. Tuttle ⁸ , on behalf of the ASI in CKD group
0059	Cumulative Effects of Vicastrostat (BI 690517) and Empagliflozin on Albuminuria in People with Chronic Kidney Disease	Peter Rossing ^{1,2} , Sibylle J. Hauske ^{3,4} , Lisa Cronin ⁵ , Hiddo J. L. Heerspink ^{6,7} , Juliane Meyerhoff ³ , Shimoli V. Shah ⁵ , Zhichao Sun ⁵ , Dick de Zeeuw ⁶ , Katherine R. Tuttle ⁸ , on behalf of the ASI in CKD group
0060	Systolic Blood Pressure Response to Aldosterone Synthase Inhibitor Vicastrostat (BI 690517) With and Without Empagliflozin in Chronic Kidney Disease	Peter Rossing ¹ , Sibylle J. Hauske ² , Lisa Cronin ³ , Hiddo J. L. Heerspink ⁴ , Juliane Meyerhoff ² , Bo Ji ³ , Dick de Zeeuw ⁵ , Katherine R. Tuttle ⁶ , on behalf of the ASI in CKD group
0061	Characteristics of Diabetes Patients with Inadequately Controlled Hypertension: Insights from the EnLIGHTN Study	Vivek Bhalla, MD ¹ , Samuel Adamsson Eryd, PhD ² , Tom Norris, PhD ² , Maghan Ballantyne, PharmD ³ , Terry McCormack, PhD ⁴
0062	A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexiide in Post-Bariatric Hypoglycemia (LUCIDITY)	Ryan Miller, MD ¹ , Marilyn Tan, MD, FACE ² , Tracey McLaughlin, MD, MS ² , Mary Elizabeth Patti, MD ³ , Suzanne Bijl, PhD ¹ , Jennifer Hardy, PharmD ¹ , Jorgji Kerthi, PharmD ¹ , Jamie Timmons, MD ¹ , Yuehui Wu, PhD ¹ , Zhengyu Yang, PhD ¹ , Lahar Mehta, MD ¹ , Colleen Craig, MD ²
0063	Investigating the Effects of Icovamenib on Poorly Managed Severe Insulin-Deficient Diabetes (SIDD): Insights from COVALENT-111 Case Studies	Alexander Abitbol, MDCM, FRCPC ¹ ; Douglas Denham, DO ² ; Apinya B. Vutikullird, DO ³ ; Adolfo Cueli, MD ⁴ ; Alexander Osowa, MD ⁵ ; Sanchita Mourya, MD ⁶ ; Brian Munneke, PhD; Jeffrey Kim, PhD; Thomas Butler, MS, MBA; Juan Pablo Frías, MD
0064	Blood C-Peptide Values are Impacted by the Collection, Storage and Evaluation Methods	Mathew Trandafirescu, BS, Rema Rasheed, BS, Ta'ir Rocker, 1st year medical student, Chassidy Ramirez, MS, Sowah Welbeck, MS, Wai Thein, MD, Minka Chikolareva, RN, BSN, MS, MBA, Oana Sandu, MD
0065	Continuous Glucose Monitoring Metrics Predict All-cause Mortality in Patients with Both Type 1 and Type 2 Diabetes Running title: CGM Metrics and All-cause Mortality	Tomoki Okuno ^{1,2} , Sharon A. Macwan ² , Gregory J. Norman ³ PhD, Donald R. Miller ⁴ , Peter D. Reaven ² MD*, and Jin J. Zhou ^{1,2} PhD*
0067	Cycloset Reduces Immune Pro-Inflammatory Status and Endothelial Dysfunction in Type 2 diabetes (T2D) Subjects on GLP-1 RA	Anthony H. Cincotta, PhD ¹ , Eugenio Cerosimo, MD, PhD ^{2,3} , Mariam Alatrach, MD ^{2,3} , Michael Ezrokhi, PhD ¹ , Christina Agyin, FNP ^{2,3} , John Adams ^{2,3} , Robert Chilton, DO ^{2,3} , Curtis Triplitt, PharmD ^{2,3} , Bindu Chamathi, MD, MMSc ¹ , Nicholas Cominos, BS ¹ and Ralph A. DeFronzo, MD ^{2,3}
0068	Revolutionizing Treatment of Peripheral Arterial Disease through Allogenic Endothelial Progenitor Cells (EPCs)	"Huiyuan Zhang ^{1,2} , Hui Shi ^{1,2} , Wenjuan Zhang ¹ , Chen Song ¹ , Yongli Han ¹ , Ping Guo ¹ , Lida Wu ^{1,2} , Shaoying Lu ³ , Yingfeng Wu ⁴ , Shengjiang Tan ^{5,6,7,8} , Yuchun Gu ^{2,8} , #
0069	Combination of Icovamenib and GLP-1-based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion	Mini Balakrishnan, PhD, Tracy Zhang, PhD, Kung-Hsien Ho, PhD, Dina Mousavi, MS, Juan Pablo Frías, MD, Thomas Butler, MS, MBA
0070	Amyloid index (AMI): A Measure of Brain Amyloid in Aging Patients	Harold T. Pretorius, M.D., Ph.D., B. Patel, M.D., Kristi Lavever, R.N, N.P., Betsy Budke, CNMT, Nichole M. Bodnar, B.S.,CNMT
0071	Association Between Markers of Adiposity and Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes	Themis Zelmanovitz, MD, PhD; Danie Weber, RD, MSc; Cristina Pavinatto, RD, MSc; Gabriela Bello, RD, MSc; Pietro Peruffo; Marina L. Harthmann; Rogerio Bender Junior; Isabella Passos; Sofia Simoni; Sandra Silveiro, MD, PhD.
0072	Turning the Tide of Obesity Medicine: Tirzepatide in the Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans with Overweight/Obesity	Jasmine Yang, BA; Nicole Turk, BS; Rachel Huynh, BA; Evelyn Yandle; Henry Chen, PhD; Natesh Saini, BS; Chun Johnston, RDN; Dalia Perelman, RD; Tracey McLaughlin, MD, MS
0073	Exploring the Role of Hypoxia-Induced HIF-1 /SMAD2/VEGF Signaling in Promoting M2 Polarization of Renal Macrophages for Potential Renoprotective Effects	Yaya Xu, Jiayue Xu, Jiru Li, Xiangmei Kong, Haoyun Mao, Zhiyi Du, Jiahui Zan, Lili Xu, Wen Qian, Zhushengying Ma, Yueniu Zhu, Xiaodong Zhu
0079	Gender Differences in Prevalence and Clinical Correlates of Dapagliflozin-Associated Diabetic Ketosis/Ketoacidosis in Patients with Type 2 Diabetes Mellitus	Maosheng Lee ^{1,2*} , Yanyan Tan ^{1,2} Siping Peng ^{1,2} , Shimao Zhang ² , Hengxia Zhao ^{1,2} , Huilin Li ^{1,2}
0081	Safety, Tolerability, and Clinical Effects of Petrelintide (ZP8396), a Long-Acting Amylin Analog	Minna Brændholt Olsen ¹ , Jon Griffin ¹ , Ulrike Hövelmann ² , Stanislava Macura ¹ , Thue Johansen ¹ , Berith Fredsted Hagen ¹ , Helle Frimer-Larsen ¹ , Evan Charles Frary ¹ , Dan Hesse ¹ , Tim Heise ²
0082	Feasibility and Safety of Novel Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in Pigs	"Timothy Kieffer, I Chris Thompson ^{2,3} , Jake Wainer ¹ , Michael Biase ¹ , Lindsay Schulman ¹ , Nicole Picard ¹ , Rebecca Reese ¹ , Alice Liou Fitzpatrick ¹ , Edward Mahoney ¹ , Emily Cozzi ¹ , Shimyn Slomovic ¹ , Jay Caplan ¹ , Harith Rajagopalan ¹ "